Clinically relevant biomarkers in targeted radiotherapy.

Area of Science:

• Oncology
• Radiation Oncology
• Molecular Biology

Background:

• Classic radiation response predictors (intrinsic radiosensitivity, hypoxia, repopulation) face clinical application challenges due to technical difficulties and time constraints.
• Molecular biology advances enable genome-wide screening for genetic signatures to predict radiotherapy outcomes.
• Epidermal growth factor receptor (EGFR) is a promising candidate, overexpressed/mutated in various cancers, with EGFR inhibition demonstrating radiosensitization.

Purpose of the Study:

• To identify predictive biomarkers for radiotherapy response.
• To explore molecularly targeted therapies for radioresistant tumors.
• To develop efficient and reproducible assays for detecting tumor genetic mutations.

Main Methods:

• Review of classic radiation response parameters and their limitations.
• Exploration of genome-wide screening methods in molecular biology.
• Discussion of epidermal growth factor receptor (EGFR) as a potential biomarker and therapeutic target.
• Consideration of stereotactic body radiotherapy (SBRT) with image-guided radiation therapy (IGRT) as a clinical approach.

Main Results:

• Significant variability exists in patient response to radiotherapy.
• EGFR inhibition shows potential for radiosensitization and improved survival.
• Targeted therapies combined with radiation could enhance response rates in radioresistant tumors.
• SBRT with IGRT allows for more aggressive radiation dosing while minimizing normal tissue toxicity.

Conclusions:

• Predictive assays for radiotherapy response are valuable for personalized treatment.
• Targeting EGFR may improve outcomes for specific cancer types.
• Molecularly targeted therapies combined with radiation offer a promising strategy to increase cure rates.
• Advanced radiation techniques like SBRT with IGRT are crucial for managing radioresistant tumors.